In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...